CN115192626A - 一种通风活络、散结保健、痛风止痛制剂及其制备方法 - Google Patents
一种通风活络、散结保健、痛风止痛制剂及其制备方法 Download PDFInfo
- Publication number
- CN115192626A CN115192626A CN202210325367.5A CN202210325367A CN115192626A CN 115192626 A CN115192626 A CN 115192626A CN 202210325367 A CN202210325367 A CN 202210325367A CN 115192626 A CN115192626 A CN 115192626A
- Authority
- CN
- China
- Prior art keywords
- weight
- preparation
- percent
- ginseng
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 230000003213 activating effect Effects 0.000 title claims abstract description 16
- 201000005569 Gout Diseases 0.000 title claims abstract description 15
- 230000036541 health Effects 0.000 title claims abstract description 14
- 230000000694 effects Effects 0.000 title abstract description 96
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 72
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 72
- 235000008434 ginseng Nutrition 0.000 claims abstract description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 16
- 239000006247 magnetic powder Substances 0.000 claims abstract description 12
- 108010010803 Gelatin Proteins 0.000 claims abstract description 11
- 229920000159 gelatin Polymers 0.000 claims abstract description 11
- 239000008273 gelatin Substances 0.000 claims abstract description 11
- 235000019322 gelatine Nutrition 0.000 claims abstract description 11
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 11
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 8
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 8
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 8
- 240000001851 Artemisia dracunculus Species 0.000 claims abstract description 8
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 8
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 8
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 8
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 241001061264 Astragalus Species 0.000 claims abstract description 7
- 235000006533 astragalus Nutrition 0.000 claims abstract description 7
- 210000004233 talus Anatomy 0.000 claims abstract description 7
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract 2
- 208000002193 Pain Diseases 0.000 claims description 34
- 239000007788 liquid Substances 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 235000011837 pasties Nutrition 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 8
- 210000003205 muscle Anatomy 0.000 abstract description 7
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 230000032683 aging Effects 0.000 abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000004310 lactic acid Substances 0.000 abstract description 4
- 235000014655 lactic acid Nutrition 0.000 abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 abstract description 4
- 239000001301 oxygen Substances 0.000 abstract description 4
- 230000035515 penetration Effects 0.000 abstract description 4
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- 230000008961 swelling Effects 0.000 abstract description 2
- 239000002699 waste material Substances 0.000 abstract description 2
- 241000208340 Araliaceae Species 0.000 description 70
- 229930182494 ginsenoside Natural products 0.000 description 22
- 229940089161 ginsenoside Drugs 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 230000006870 function Effects 0.000 description 16
- 230000004060 metabolic process Effects 0.000 description 16
- 201000010099 disease Diseases 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 208000014674 injury Diseases 0.000 description 12
- 229930182490 saponin Natural products 0.000 description 12
- 235000017709 saponins Nutrition 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 9
- 150000004676 glycans Chemical class 0.000 description 9
- 230000036737 immune function Effects 0.000 description 9
- 239000002674 ointment Substances 0.000 description 9
- 229920001282 polysaccharide Polymers 0.000 description 9
- 239000005017 polysaccharide Substances 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 238000005728 strengthening Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 230000008736 traumatic injury Effects 0.000 description 9
- 208000032843 Hemorrhage Diseases 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 8
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 8
- 235000010894 Artemisia argyi Nutrition 0.000 description 7
- 206010005963 Bone formation increased Diseases 0.000 description 7
- 206010050031 Muscle strain Diseases 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 244000030166 artemisia Species 0.000 description 7
- 230000000740 bleeding effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 210000003710 cerebral cortex Anatomy 0.000 description 7
- 230000005284 excitation Effects 0.000 description 7
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- -1 panaxatriol saponin Chemical class 0.000 description 7
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 210000003141 lower extremity Anatomy 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 210000001364 upper extremity Anatomy 0.000 description 6
- 241000255925 Diptera Species 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 238000003759 clinical diagnosis Methods 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 206010000234 Abortion spontaneous Diseases 0.000 description 4
- 241000125175 Angelica Species 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 235000001287 Guettarda speciosa Nutrition 0.000 description 4
- 208000019255 Menstrual disease Diseases 0.000 description 4
- 206010027514 Metrorrhagia Diseases 0.000 description 4
- 208000000112 Myalgia Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- SYFJYASKXNAXKC-UHFFFAOYSA-N Panaxadiol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CCC34C SYFJYASKXNAXKC-UHFFFAOYSA-N 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 229940107131 ginseng root Drugs 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 208000015994 miscarriage Diseases 0.000 description 4
- 229960005181 morphine Drugs 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 208000000995 spontaneous abortion Diseases 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 206010002660 Anoxia Diseases 0.000 description 3
- 241000976983 Anoxia Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 206010049771 Shock haemorrhagic Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000013465 muscle pain Diseases 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 239000011505 plaster Substances 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 208000005198 spinal stenosis Diseases 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 2
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010017577 Gait disturbance Diseases 0.000 description 2
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 2
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside Rg2 Natural products O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- VIXIMKLMEZTTTC-UHFFFAOYSA-N Panaxatriol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C VIXIMKLMEZTTTC-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 241000607762 Shigella flexneri Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- CNHRRMQBWQJRPN-UHFFFAOYSA-N chikusetsusaponin LM5 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CNHRRMQBWQJRPN-UHFFFAOYSA-N 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 230000000001 effect on platelet aggregation Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 2
- 229940114124 ferulic acid Drugs 0.000 description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 2
- 235000001785 ferulic acid Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 238000003958 fumigation Methods 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 2
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 description 2
- JDCPEKQWFDWQLI-LUQKBWBOSA-N ginsenoside Rc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O JDCPEKQWFDWQLI-LUQKBWBOSA-N 0.000 description 2
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 2
- SPFXZQZPHXUJSR-UHFFFAOYSA-N ginsenoside-Rc Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1OC2OC(CO)C(O)C2O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C SPFXZQZPHXUJSR-UHFFFAOYSA-N 0.000 description 2
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 230000001456 gonadotroph Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000024765 knee pain Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000008558 metabolic pathway by substance Effects 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical group C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 2
- 229960001999 phentolamine Drugs 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 description 1
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- NFZYDZXHKFHPGA-UHFFFAOYSA-N 17alpha-hydroxygofruside Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(C(O)=O)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NFZYDZXHKFHPGA-UHFFFAOYSA-N 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- QXQFFGOMXYKNBA-UHFFFAOYSA-N Chikusetsusaponin V Natural products CC1(C)CCC2(CCC3C(=CCC4C3(C)CCC5C(C)(C)C(CCC45C)OC6OC(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O QXQFFGOMXYKNBA-UHFFFAOYSA-N 0.000 description 1
- NFZYDZXHKFHPGA-QQHDHSITSA-N Chikusetsusaponin-V Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NFZYDZXHKFHPGA-QQHDHSITSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 208000001375 Facial Neuralgia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010061191 Haemorrhage foetal Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 101100408105 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) phi gene Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101000669434 Mus musculus Transducin-like enhancer protein 1 Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108010052989 Naphthol AS D Esterase Proteins 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000228150 Penicillium chrysogenum Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241001540751 Talaromyces ruber Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 206010056697 Tissue anoxia Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002587 anti-hemolytic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000703 anti-shock Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000001201 calcium accumulation Effects 0.000 description 1
- 230000008061 calcium-channel-blocking effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 208000012790 cranial neuralgia Diseases 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000000816 effect on animals Effects 0.000 description 1
- 230000000212 effect on lymphocytes Effects 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 229940029988 ginseng preparation Drugs 0.000 description 1
- RBRANZURTULKJD-UHFFFAOYSA-N ginsenoside Ro Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(C)(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C(C)(C)C5CCC34C)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O RBRANZURTULKJD-UHFFFAOYSA-N 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005056 memory consolidation Effects 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- PFBSOANQDDTNGJ-YNHQPCIGSA-N morphinone Chemical compound O([C@H]1C(C=C[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O PFBSOANQDDTNGJ-YNHQPCIGSA-N 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- UICBCXONCUFSOI-UHFFFAOYSA-N n'-phenylacetohydrazide Chemical compound CC(=O)NNC1=CC=CC=C1 UICBCXONCUFSOI-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000003270 subclavian artery Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Botany (AREA)
- Neurology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种通风活络、散结保健、痛风止痛制剂及其制备方法,其特征在于:包括10‑30%重量份数的药物活性成分和70‑90%重量份数的基底液,所述基底液是由以透明质酸0.1%‑1%重量份数、1%‑2%远红外磁性粉,明胶0.1%‑0.5%、甘油8%‑12%、乙醇50%‑70%、水5%‑10%制备得到;药物活性成分由以下重量份数的原料制备得到:人参重量份:20%;黄芪重量份:15%;当归重量份:30%;艾草重量份:35%。在辅料中加入了远红外粉与磁性粉,远红外粉产生的远红外线深透力可达肌肉关节深处,使身体内部温暖,放松肌肉,带动微血管网的氧气及养分交换,并排除积存体内的疲劳物质和乳酸等老化废物对消除内肿,缓和酸痛之效果卓越,扩张微血管,促进血液循环,有利于药物的渗透和利用。
Description
技术领域
本发明属于医药技术领域,尤其涉及一种通风活络、散结保健、痛风止痛制剂及其制备方法。
背景技术
筋骨疼痛、跌打损伤、风湿痹痛是临床常见症状,几乎每个人在生活多都会遇到类似症状,比如运动后的肌肉酸痛,肌肉拉伤,关节扭伤等,这类疾病虽然不会带来生命危险,但却会使人们行动不便,饱受疼痛干扰,严重影响了人们的日常生活质量。
发明内容
本发明的目的在于提供一种通风活络、散结保健、痛风止痛制剂及其制备方法,旨在解决所述背景技术中存在的问题。为实现所述目的,本发明采用的技术方案是:
一种通风活络、散结保健、痛风止痛制剂及其制备方法,包括。
本发明所用原料的性味归经、功能主治、主要成分及药理作用如下:
人参:人参味甘、微苦、性微温。归脾、肺、心、肾经,是补虚扶正大补元气之要药。具有大补元气、复脉固脱、补脾益肺、生经养血、安神益智之功效。
药理作用:
1.对中枢神经系统的作用:
人参及其不同制剂、不同成分,对中枢神经系统的生理功能均具有调节作用。
①兴奋与抑制作用:
人参对高级神经系统的兴奋和抑制过程均有加强作用,并以兴奋作用更为显著。人参的水醇浸膏可兴奋大脑皮质,增强大脑皮层兴奋与抑制过程的活动反应,加强胆碱能神经功能,并使血压下降、呼吸兴奋。人参皂苷的混合物也有中枢兴奋和抗疲劳等作用。人参皂苷(Rb和Rc的混合物)(GNS)对小鼠有安定、镇静、中枢性肌肉松弛、降温、减少自发活动等作用。人参对中枢神经系统有兴奋与抑制的双向作用。人参皂苷Rg类有中枢兴奋作用,而Rb类则呈现镇静作用。人参对猫的脑电图可产生中等程度脑电波的同步化作用(即增强抑制过程),也可增强兴奋剂的异步化作用,对癫痫性脑电波的棘波则呈现频率增加及波幅增大,且使棘波泛化(兴奋过程加强)。人参对中枢神经系统的作用与该系统的功能状态、用药剂量以及人参的不同成分有关。
②对学习记忆的影响:
人参及其制剂在提高学习能力、易化记忆方面有明显的促进作用,而且对记忆的各阶段均有影响。人参对多种化学品造成的实验动物记忆获得障碍、记忆巩固障碍和记忆再现障碍的改善随人参化学组分的不同而异,人参皂苷Rg1和Rb1效果较好,以Rg1最佳。人参对学习记忆的影响与剂量也有关,当超出一定剂量范围时可产生阻抑作用。
③对脑内物质代谢的影响:
人参对蛋白质、RNA和DNA的合成有促进作用。人参通过影响脑内单胺类递质和胆碱能神经对中枢起作用。人参皂苷Rg1、Rb1是促智的主要有效成分,能增加Ach的合成和释放,提高中枢M受体的密度。人参根给小鼠连续灌服,能加强小鼠大脑皮层中DA、 NA和纹状体、小脑中5-HT的代谢,而中脑、丘脑下部的5-HT和纹状体中DA的代谢却被抑制。人参能促进脑内单胺物质合成的前体物苯丙酸透过血脑屏障,这有利于中枢的DA 和NA的合成。人参还能特异性并且剂量依赖性地抑制DA、NA和5-HT摄取入大鼠脑突触体中,也能特异性且剂量依赖性地抑制GABA和谷氨酸摄取入大脑突触体内,只是低剂量时谷氨酸转运较敏感,而在高剂量时GABA转运较敏感。人参皂苷对不同年龄大鼠大脑皮层Na+,K+-ATP酶和Ca2+-ATP酶的活力有不同的作用,能显著抑制成年大鼠大脑皮层Na+,K+-ATP酶和Ca2+-ATP酶的活力,对老年大鼠大脑皮层的Na+,K+-ATP酶和 Ca2+-ATP酶的活力则具有显著地兴奋作用,对新生大鼠的大脑皮层Na+,K+-ATP酶和 Ca2+-ATP酶的活力无明显影响。
④对脑血流量和脑能量代谢的影响:
人参皂苷静脉注射能显著阻止大鼠实验性脑缺血和再灌注过程中皮层脑电图发生严重抑制和脑水肿形成,又能抑制脑组织细胞LDH、SOD活性下降和MDA含量及颈动脉血中LDH活性升高,同时能增加脑血流量,减少钙积累,延长双侧锁骨下和颈总动脉结扎后自主呼吸和脑电活动时间,并促进再灌注恢复。此外,人参可增加兔脑葡萄糖的摄取,同时减少乳酸、丙酮酸和乳酸/丙酮酸的比值,并可使葡萄糖的利用从无氧代谢转变为有氧代谢。
2.对机体免疫功能的影响:
①对网状内皮系统吞噬功能的影响:
人参皂苷对多种动物网状内皮系统吞噬功能均有明显的激活作用,能增强其吞噬能力,并使血清溶菌酶含量显著升高。人参多糖无论是灌胃或腹腔注射对小鼠的免疫功能均有促进作用。人参可明显提高MΦ内糖原和粘多糖、酸性磷酸酶、α-醋酸萘酯酶和ATP 酶的含量,说明MΦ合成与贮存糖原增加,消化力增强。人参根总皂苷灌胃给药,对环磷酰胺所致小鼠白细胞数减少有明显回升作用,对MΦ吞噬功能抑制、溶血素形成抑制和 DTH均有恢复正常的作用。
②对抗体形成的影响:
人参对各种抗原刺激后的动物抗体产生有明显的促进作用。人参皂苷免疫调节作用与机体免疫状态有关。人参根多糖能使绵羊红细胞免疫的小鼠血清中IgH的含量明显升高。人参水煎剂小鼠灌服对绵羊红细胞激发的1次和2次抗体形成均有促进作用,且与剂量相关,能在小鼠活体内明显增强特异性抗绵羊红细胞抗体形成细胞反应,但对脾淋巴细胞总数无明显影响。
③对淋巴细胞转化的影响:
人参皂苷小鼠皮下注射对LPS和ConA刺激的淋巴细胞转化有显著的增强作用。在体外,人参皂苷对各种多裂原刺激的淋巴细胞增殖反应促进作用最为明显,浓度过高或过低都会影响这一效应。人参皂苷对淋巴细胞的自发转化仅有较弱的促进作用。人参皂苷Rd对氢化可的松所致的免疫抑制小鼠的体外ConA刺激淋巴细胞转化也有明显的增强作用,并可使其完全恢复至正常水平。Re也有相同的增强作用。人参皂苷经导管直接导入双侧海马,能明显增强大鼠脾脏和胸腺T淋巴细胞ConA增殖反应,促进IL-2的产生和表达。人参三醇皂苷可促进IL-3基因表达,最终促IL-3的合成。NK活性恢复也较快,同时抑制应激期ACTH和皮质酮的增加。
④对免疫功能的影响与环核苷酸的关系:
人参根总皂苷对环核苷酸的影响随机体免疫反应水平不同而呈现双向调节作用,当人参使溶血素水平升高时,cAMP含量多数降低,当溶血素水平降低时,cAMP含量多数升高,而cGMP含量多数降低。
⑤对荷瘤动物免疫功能的影响:
人参多糖可使荷瘤机体免疫功能增强,对荷瘤而致免疫功能低下有较好的保护作用。人参皂苷对荷瘤小鼠NK活性与瘤块的重量呈负相关。并且荷瘤小鼠的脾脏明显增生,胸腺明显缩小,可使受试小鼠荷瘤率降低,瘤重低于对照组,NK活性、γ-IFN及IL-2值高于对照组。
3.对心血管系统的作用:
①对心脏的影响:
人参对多种动物心脏呈现先兴奋后抑制,小剂量兴奋、大剂量抑制的作用;能延长缺氧条件下的离体豚鼠心房收缩的持续时间,减少缺血心脏冠状窦中的乳酸含量。人参煎剂还可显著增加心肌营养血流量,抑制大鼠心肌细胞膜Na+,K+-ATP酶的活性。人参皂苷Ro、Rb1、Rb2、Rc、Rd、Rg1、Rg2、Rg3等具有较强的抗BaCl2诱发的大鼠心律失常作用,纠正心动过速,并使其恢复到正常水平。人参二醇组皂苷和人参三醇组皂苷有钙通道阻滞作用。较低剂量人参总皂苷及其组分Rb+Ro能保护乳鼠心肌细胞培养缺糖缺氧性损伤;对心肌缺氧和再灌注有保护作用。人参总皂苷腹腔注射能降低小鼠严重缺氧心肌的乳酸含量,改善组织缺氧时的能量代谢。
②对血管及血压的影响:
人参对血管的作用因血管的种类不同或机体状态的不同而表现不同。一般认为人参是血管扩张药,但也有小剂量收缩大剂量扩张,或先收缩后扩张的报告。人参的水溶性组分可升高血压,这种升压作用不被六甲季胺和酚妥拉明阻断;中性皂苷组GNS、GRb1、GRg1等可降低血压,这种降压作用不被阿托品、酚妥拉明及普萘洛尔所抑制,其中GNS和GRb1 的降压作用稍持久。
③抗休克作用:
人参二醇皂苷预先静脉注射,对失血性休克的心功能有明显的保护作用,增强心肌收缩力,改善血流动力学状态。人参二醇皂苷预先静脉注射可明显提高内毒素性休克大鼠的存活率,能抑制失血性休克犬细胞内酶的释放,人参二醇皂苷对失血性休克犬动脉血氧分压和动脉血血氧含量代偿性增加的程度略高于地塞米松组,并使血液pH值明显下降的时间迟于地塞米松组,而且下降的程度也较小。人参对失血性和窒息性垂危状态中的犬有促进恢复正常生命活力的作用。
4.对血液和造血系统的影响:
人参或人参提取物对骨髓的造血功能有保护和刺激作用,可使正常和贫血动物红细胞数、白细胞数和Hb量增加。当外周血细胞或骨髓受到抑制时,人参增加外周血细胞数的作用更为明显。人参对乙酰苯肼造成的小鼠和兔溶血性贫血有治疗作用,使红细胞和Hb 量均增加。Rb1促进血小板聚集,Rg1、Re抑制血小板聚集。Rg1、Rg2对ADP诱导的血小板聚集有抑制作用,Ro、Rg1对胶原诱导的聚集有抑制作用,Rg1对AA和TXA2诱导的血小板聚集也有抑制作用。人参不同部位皂苷的溶血活性存在明显差异,主根和侧根有溶血作用,全参和须根没有溶血活性。人参皂苷Rb1、Rb2、Rc具有显著的抗溶血作用。
5.对内分泌系统的作用:
人参本身无肾上腺皮质激素样作用,但对垂体-肾上腺皮质系统有刺激作用,其有效成分为人参皂苷。人参能兴奋垂体分泌促性腺激素,对去垂体大鼠人参的促性激素样作用不复出现。人参醇提物可使兔垂体前叶促甲状腺激素释放增加,人参短时间大量应用,可加强兔的甲状腺功能;较长期应用,则呈抑制作用。人参总皂苷可以刺激分离的大鼠胰岛释放胰岛素,并可促进葡萄糖引起的胰岛素释放。
6.对物质代谢的影响:
①对糖代谢的影响:
人参及其有效成分对正常及各种实验性高血压动物的糖代谢有着较为复杂的影响,对血糖水平具有调整作用,可使紊乱的代谢过程得以正常化。人参给药后4小时才能引起肝糖原降低,而在给药8小时其作用最为显著,且高剂量作用较强。
②对脂质代谢的影响:
人参影响脂类代谢的有效成分,除人参皂苷之外,还有多肽类物质等。人参皂苷既促进TC的合成,又能加速TC随胆汁经肠道排出。口服人参皂苷能显著抑制TC的吸收,长期服用人参能降低血中TC浓度,对AS症有防治作用。
③对蛋白质代谢的影响:
人参可使雌性大鼠蛋白质合成加强,食欲增加、体重增长、生长加快,并能矫正雌鼠因饥饿出现的肝DNA减少,促进蛋白质合成。人参组分NG3及NG4使大鼠肝细胞核中 DNA依赖性RNA多聚酶活性增加,促进标记的乳清酸掺入肝细胞核RNA中,引起粗面内质网膜附着型重多聚核糖体及分泌型蛋白质合成增加,故称NG3、NG4为蛋白质合成促进因子,其活性成分为人参皂苷,主要为Rb1、Rb2、Re、Rg1、Rc,其中Rb2、Rc、Rg1 能明显增加大鼠骨髓细胞DNA、蛋白质的合成。
④对水盐代谢的影响:
人参不同部位对机体的水盐代谢均有明显影响,显示出抗利尿作用。动物用药后,可产生水钠储留和排钾作用,使钠/钾比值降低。人参不同部位的皂苷可能是人参中影响水盐代谢的有效成分。
7.抗肿瘤作用:
人参制剂以及人参不同药用部位所含的多种皂苷、人参多糖和人参挥发油均显示具有抗肿瘤作用。人参多糖可能是由于其调整了机体的免疫功能,使荷瘤宿主增强了抗肿瘤能力而显示其抗肿瘤作用,人参皂苷则可能是由于直接作用于癌细胞,使其生长受到抑制或逆转,也可能是通过对代谢的影响和对免疫功能的调节作用,使机体对疾病的抵抗力增强,从而使肿瘤的生长受到抑制。人参挥发油可能是由于抑制了癌细胞的核酸代谢、糖代谢及能量代谢。人参除本身具有抗肿瘤作用外,也是抗肿瘤药的增效剂。
8.抗衰老作用:
人参具有广泛的调节内分泌、抗氧化、增加物质代谢、提高机体免疫功能等作用,能对衰老机体的各种生理生化变化起到良好的调整作用,从而显示其抗衰老的作用。人参挥发油可通过皮肤的渗透作用为人体所吸收,从而促进血液循环和新陈代谢,增进皮肤细胞的发育营养和光泽,具有防皱和抗寒冷与抗紫外线辐射作用。
9.对机体应激能力的影响:
人参能加强机体的适应性,通过对神经系统、内分泌、免疫功能和代谢等多方面的影响增强机体对物理、化学和生物等各种有害刺激或损伤的非特异性抵抗力,使紊乱的功能恢复正常。人参能使大鼠肾上腺内维生素C含量明显降低,但使处于应激反应中明显下降的肾上腺内维生素C含量得以回升,从而保护肾上腺皮质功能免于衰竭;此外人参抗应激作用与兴奋动物的下丘脑-垂体-肾上腺皮质系统的功能也有着密切的关系。
10.其他作用:
①抗溃疡作用:
人参甲醇提取物对大鼠多种实验性溃疡有抑制作用,并能抑制氨基吲哚和内毒素引起的胃粘膜血流障碍。人参多糖能明显抑制盐酸、乙醇诱导的小鼠胃粘膜损伤。
②对抗吗啡戒断症状:
人参皂苷可明显抑制吗啡的戒断症状,能有效地阻断吗啡酮的生成,解除吗啡对脑内释放神经递质的抑制,从而防止吗啡耐受性和成瘾性。
③抗菌作用:
不同浓度的参须液对福氏痢疾杆菌Y变种、福氏痢疾杆菌Ⅰa型、乙型溶血性链球菌、产紫青霉菌均有抑制作用。较高浓度对金黄色葡萄球菌、大肠艾希杆菌、炭疽杆菌、肺炎杆菌、黑色曲霉菌、产黄青霉菌有抑制作用。人参根皂苷对感染金黄色葡萄球菌、大肠杆菌、宋氏痢疾杆菌或伤寒杆菌的动物具有良好的非特异性抗感染作用。
黄芪:健脾补中,升阳举陷,益卫固表,利尿,托毒生肌。药理作用:黄芪能促进机体代谢、抗疲劳、促进血清和肝脏蛋白质的更新;有明显的利尿作用,能消除实验性肾炎尿蛋白;能改善贫血动物现象;能升高低血糖,降低高血糖;能兴奋呼吸;能增强和调节机体免疫功能,对干扰素系统有促进作用,可提高机体的抗病力;对流感病毒等多种病毒所致细胞病变有轻度抑制作用,对流感病毒感染小鼠有保护作用;有较广泛的抗菌作用;黄芪在细胞培养中,可使细胞数明显增多,细胞生长旺盛,寿命延长;能增强心肌收缩力,保护心血管系统,抗心率失常,扩张冠状动脉和外周血管,降低血压,能降低血小板粘附力,减少血栓形成;还有降血脂、抗衰老、抗缺氧、抗辐射、保肝等作用;
当归:甘、辛,温,归肝、心、脾经,补血活血,调经止痛,润肠通便,用于血虚萎黄,眩晕心悸,月经不调,经闭痛经,虚寒腹痛,风湿痹痛,跌扑损伤,痈疽疮疡,肠燥便秘;酒当归活血通经,用于经闭痛经,风湿痹痛,跌扑损伤。主要含有挥发油类、藁本内酯、正丁酰内酯,以及阿魏酸、多糖类、油脂类成分。药理研究表明,当归能明显增强巨噬细胞的作用,当归多糖能增强机体的体液免疫功能,对T淋巴细胞有较强的活化作用,对人脾细胞具有促进有丝分裂活性,当归阿魏酸对四型变态反应均有抑制作用;
艾草:
性味:苦、辛、温。归经:入脾、肝、肾。功效:回阳、理气血、逐湿寒、止血安胎。主治:治月经不调﹑经痛腹痛﹑流产﹑子宫出血,根治风湿性关节炎﹑头风﹑月内风等。全草有调经止血﹑安胎止崩﹑散寒除湿之效。治月经不调﹑经痛腹痛﹑流产﹑子宫出血,根治风湿性关节炎﹑头风﹑月内风等。因它可削冰令圆,又可炙百病,为医家最常用之药。现代实验研究证明,艾叶具有抗菌及抗病毒作用;平喘、镇咳及祛痰作用;止血及抗凝血作用;镇静及抗过敏作用;护肝利胆作用等。艾草可作“艾叶茶”、“艾叶汤”、“艾叶粥”等食谱,以增强人体对疾病的抵抗能力。艾草具有一种特殊的香味,这特殊的香味具有驱蚊虫的功效,所以,古人常在门前挂艾草,一来用于避邪,二来用于赶走蚊虫。
长期使用艾草叶的副作用:如果挥发油(香味成分)使用过多,对神经会有抑制。
艾草苦燥辛散,能理气血、温经脉、逐寒湿、止冷痛,为妇科要药。用治脘腹冷痛,经寒不调,宫冷不孕等证,如艾附暖宫丸。炒炭止血,可用治虚寒性月经过多,崩漏带下,妊娠胎漏,如胶艾汤。本品捣绒,制成艾条、艾柱,外灸能散寒止痛,温煦气血。煎汤外洗可治湿疮疥癣,祛湿止痒。
中医记载:蕲艾,味苦而辛,无毒,洗熏服用皆可。能温中、逐冷、除湿,治多种疾病。《本草纲目》载:蕲艾“炙百病。可作煎,止吐血下痢,下部匿疮,妇人漏血,利阴气;生肌肉,辟风寒,使人有子。作煎勿令见风,捣汁股,止伤血,杀蛔虫,水煮及丸散任用。止崩血,肠痔血,拓金疮,止腹痛,安胎。苦酒作煎,治癣甚良,……”。
蕲艾“服之则走三阴而逐一切寒湿,转肃杀之气为融和;炙之则透诸经而治百种病邪,起沉疴之人为康寿。其功亦大矣。”蕲艾除能治多种疾病外,还具有异香,枝叶熏烟能驱蚊蝇,清瘴气,具有禳毒杀毒的功能。后世研究认为,蕲艾有理气血、逐寒湿、调经安胎、温经止血、清热止咳消痰等功效。主治月经不调、腹中冷痛、胎漏下血、胎动不安、宫寒不孕等症。为中医妇科常用的要药之一。内服可做止血剂,炒炭用止血之力颇优,可治吐血下痢,衄血下血。捣汁服,止伤血,杀蛔虫,治带下,止霍乱转筋,痢后寒热。用蕲艾配方,亦能治老年人慢性支气管炎、哮喘、肠胃炎及痢疾等症。
蕲艾外用可治皮肤瘙痒、阴痒湿疹及疥癣等。以艾搓手洗污或煎水浴身,可防治皮肤病。对于产妇和婴儿,洗用艾叶可以消毒强身。将艾叶晒干捣碎如绒,称“艾绒”,制成艾柱,燃炙经穴,或染麻油引火点炙柱,滋润炙疮,至愈不痛。炙疾有奇效,能散寒除湿,温通气血,通经活络,故医家谓艾可炙百病(《名医别录》),称之为炙草。用艾灼一次,为之“一壮”。蕲艾不仅治疗多种疾病,还具有异香,可以作调香原料。枝叶熏烟能驱蚊蝇,具禳毒杀菌的功效。“清明插柳,端午插艾”,蕲春人更是把蕲艾蕲艾比一般艾更香,入药治病疗效更好。
一种通风活络、散结保健、痛风止痛制剂,包括10-30%重量份数的药物活性成分和 70-90%重量份数的基底液,所述基底液是由以透明质酸0.1%-1%重量份数、1%-2%远红外磁性粉,明胶0.1%-0.5%、甘油8%-12%、乙醇50%-70%、水5%-10%制备得到;
药物活性成分由以下重量份数的原料制备得到:
人参重量份:20%;
黄芪重量份:15%;
当归重量份:30%;
艾草重量份:35%。
一种通风活络、散结保健、痛风止痛制剂的制备方法,所述方法用于权利要求1制剂的制作,包括以下步骤:
S1:取处方量的药材,通过研磨机粉碎成药粉,再往药粉中加入3-5倍重量的水进行浸泡1-3h,将浸泡后的混合液进行加热熬煮,使得各中药活性分子充分融入水溶液中;
S2:将加热后的水溶液静置并进行过滤,将滤液冷却备用;
S3:进行基底液的制作,将透明质酸0.1%-1%、远红外粉/磁性粉1%-2%、明胶0.1%-0.5%、甘油8%-12%、乙醇50%-70%、水5%-10%进行充分搅拌5-10分钟;
S4:将S3中的基底液和S2中的滤液进行充分的搅拌混合5-15分钟,得到本中药剂液态体;
S5:称取乙二胺四乙酸二钠,加水溶解,将聚维酮K30和明胶混合后加入,在50-80℃的条件下加热溶解,得中间质,将中间质和步骤S4制得的中药剂液态体混合,在50-80℃的条件下搅拌0.5-2h,得膏状中药制剂。
本发明的有益效果:
在辅料中加入了远红外粉与磁性粉,远红外粉产生的远红外线深透力可达肌肉关节深处,使身体内部温暖,放松肌肉,带动微血管网的氧气及养分交换,并排除积存体内的疲劳物质和乳酸等老化废物对消除内肿,缓和酸痛之效果卓越,同时远红外线可以使皮下深层皮肤温度上升,扩张微血管,促进血液循环,有利于药物的渗透和利用。
磁性粉产生的特定电磁波谱很容易被生物体吸收,产生对生物有益的生物效应,从而提高生物体内各种酶的活性,改善生物体内的微循环系统,提高和调动生物体自身的免疫功能,产生出更多的免疫体液,减轻痛症。
远红外粉与磁性粉同时可以促进药物的快速吸收,提高药物的利用率,从而使本发明风湿贴起效迅速、疗效好。
附图说明
图1为本发明制剂实测红外辐射能谱图。
具体实施方式
为了便于理解本发明,下面将参照相关附图对本发明进行更全面的描述。附图中给出了本发明的较佳实施方式。但是,本发明可以以许多不同的形式来实现,并不限于本文所描述的实施方式。相反地,提供这些实施方式的目的是使对本发明的公开内容理解的更加透彻全面。
需要说明的是,当元件被称为“固定于”另一个元件,它可以直接在另一个元件上或者也可以存在居中的元件。当一个元件被认为是“连接”另一个元件,它可以是直接连接到另一个元件或者可能同时存在居中元件。相反,当元件被称作“直接在”另一元件“上”时,不存在中间元件。本文所使用的术语“垂直的”、“水平的”、“左”、“右”以及类似的表述只是为了说明的目的,并不表示是唯一的实施方式,本文所使用的术语“上端”、“下端”、“左侧”、“右侧”、“前端”、“后端”以及类似的表达是参考附图的位置关系。
除非另有定义,本文所使用的所有的技术和科学术语与属于本发明的技术领域的技术人员通常理解的含义相同。本文中在本发明的说明书中所使用的术语只是为了描述具体的实施方式的目的,不是旨在于限制本发明。本文所使用的术语“及/或”包括一个或多个相关的所列项目的任意的和所有的组合。
下面结合具体实施方式对本专利的技术方案作进一步详细地说明。
图1所示,本发明实施例提供了一种通风活络、散结保健、痛风止痛制剂及其制备方法,包括
一种通风活络、散结保健、痛风止痛制剂,包括10%重量份数的药物活性成分和90%重量份数的基底液,所述基底液是由以透明质酸0.1%重量份数、1%远红外磁性粉,明胶 0.1%%、甘油8%、乙醇50%、水10%制备得到;
药物活性成分由以下重量份数的原料制备得到:
人参重量份:20%;
黄芪重量份:15%;
当归重量份:30%;
艾草重量份:35%。
一种通风活络、散结保健、痛风止痛制剂的制备方法,所述方法用于权利要求1制剂的制作,包括以下步骤:
S1:取处方量的药材,通过研磨机粉碎成药粉,再往药粉中加入3-5倍重量的水进行浸泡1-3h,将浸泡后的混合液进行加热熬煮,使得各中药活性分子充分融入水溶液中;
S2:将加热后的水溶液静置并进行过滤,将滤液冷却备用;
S3:进行基底液的制作,将透明质酸0.1%-1%、远红外粉/磁性粉1%-2%、明胶0.1%-0.5%、甘油8%-12%、乙醇50%-70%、水5%-10%进行充分搅拌5-10分钟;
S4:将S3中的基底液和S2中的滤液进行充分的搅拌混合5-15分钟,得到本中药剂液态体;
S5:称取乙二胺四乙酸二钠,加水溶解,将聚维酮K30和明胶混合后加入,在50-80℃的条件下加热溶解,得中间质,将中间质和步骤S4制得的中药剂液态体混合,在50-80℃的条件下搅拌0.5-2h,得膏状中药制剂。
实施例二:
一种通风活络、散结保健、痛风止痛制剂,包括30%重量份数的药物活性成分和70%重量份数的基底液,所述基底液是由以透明质酸1%重量份数、1%远红外磁性粉,明胶0.5%、甘油12%、乙醇70%、水5%制备得到;
药物活性成分由以下重量份数的原料制备得到:
人参重量份:20%;
黄芪重量份:15%;
当归重量份:30%;
艾草重量份:35%。
临床实验数据
采用按照实施例1制备的健骨止痛药膏,进行临床实验调查:
临床试验中,选取100例患者,症状为结节、痛风、腰肌劳损、骨质增生、跌打损伤、腰椎间盘突出、上下肢各关节疼痛等症的一种或几种。
用药方法:外敷健骨止痛药膏,一周1次,2个月为一个疗程。
疗效标准:
显效:骨质增生、肩固态、跌打损伤、腰椎间盘突出、椎管狭窄、腰肌劳损、上下肢各关节疼痛等症带来的疼痛基本消失或明显减轻;
有效:骨质增生、肩固态、跌打损伤、腰椎间盘突出、椎管狭窄、腰肌劳损、上下肢各关节疼痛等症带来的疼痛有所减轻;
无效:以上症状均未见起色。
统计结果:用药2个疗程后,在100例患者中,有65例患者的骨质增生、肩固态、跌打损伤、腰椎间盘突出、椎管狭窄、腰肌劳损、上下肢各关节疼痛等症带来的疼痛基本消失或明显减轻,为显效;有33例患者骨质增生、肩固态、跌打损伤、腰椎间盘突出、椎管狭窄、腰肌劳损、上下肢各关节疼痛等症带来的疼痛有所减轻,为有效;有2例患者以上症状均未减轻,视为无效。
临床试验结果显示:一种健骨止痛药膏,其显效率为65%,有效率33%,无效率为2%,总有效率为98%。说明该药膏治疗骨质增生、肩固态、跌打损伤、腰椎间盘突出、椎管狭窄、腰肌劳损、上下肢各关节疼痛等症疗效显著。
典型病例
病例1:
甲,女,71岁,自由职业者。患病史十年有余,临床诊断为:关节增生、双腿疼、两膝盖疼痛,行走困难,敷用健骨止痛药膏3个疗程后,病情明显减轻,疼痛消失。
病例2:
乙,男,72岁,绢纺厂职工。患病史八年有余,临床诊断为:风湿疼痛、两膝盖疼痛,行走困难,敷用健骨止痛药膏2个疗程后,病情消失,行走自如。
病例3:
丙,女,29岁,城管处职工。患病史三十余年,临床诊断为:腰椎间盘突出,椎管狭窄,双膝盖增生肿大,双腿走路呈弓形,腰弯不能直立,无法行走,大小便不能自理,敷用健骨止痛药膏3个疗程后,病情明显减轻,能够独立行走,生活自理。
病例4:
丁,女,78岁,自由职业者。患病史二十年有余,临床诊断为:腰腿疼、脚部增生、面部神经痛,敷用健骨止痛药膏2.5个疗程后,疼痛基本消失,活动自如,显效明显。
病例5:
戊,女,35岁,中平能化集团六矿职工。患病史三年有余,临床诊断为:腰腿疼、骨质增生、上部颈椎病,敷用健骨止痛药膏1个疗程后,病情明显减轻,活动、行走自如。
以上实施方式仅用于说明本发明,而并非对本发明的限制,有关技术领域的普通技术人员,在不脱离本发明的精神和范围的情况下,还可以做出各种变化和变型,因此所有等同的技术方案也属于本发明的范畴,本发明的专利保护范围应由权利要求限定。
Claims (2)
1.一种通风活络、散结保健、痛风止痛制剂,其特征在于:包括10-30%重量份数的药物活性成分和70-90%重量份数的基底液,所述基底液是由以透明质酸0.1%-1%重量份数、远红外磁性粉1%-2%重量份数,明胶0.1%-0.5%重量份数、甘油8%-12%重量份数、乙醇50%-70%重量份数、水5%-10%重量份数制备得到;
药物活性成分由以下重量份数的原料制备得到:
人参重量份:20%;
黄芪重量份:15%;
当归重量份:30%;
艾草重量份:35%。
2.一种通风活络、散结保健、痛风止痛制剂的制备方法,其特征在于,所述方法用于权利要求1制剂的制作,包括以下步骤:
S1:取处方量的药材,通过研磨机粉碎成药粉,再往药粉中加入3-5倍重量的水进行浸泡1-3h,将浸泡后的混合液进行加热熬煮,使得各中药活性分子充分融入水溶液中;
S2:将加热后的水溶液静置并进行过滤,将滤液冷却备用;
S3:进行基底液的制作,将透明质酸0.1%-1%、远红外粉/磁性粉1%-2%、明胶0.1%-0.5%、甘油8%-12%、乙醇50%-70%、水5%-10%进行充分搅拌5-10分钟;
S4:将S3中的基底液和S2中的滤液进行充分的搅拌混合5-15分钟,得到本中药剂液态体;
S5:称取乙二胺四乙酸二钠,加水溶解,将聚维酮K30和明胶混合后加入,在50-80℃的条件下加热溶解,得中间质,将中间质和步骤S4制得的中药剂液态体混合,在50-80℃的条件下搅拌0.5-2h,得膏状中药制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210325367.5A CN115192626A (zh) | 2022-03-29 | 2022-03-29 | 一种通风活络、散结保健、痛风止痛制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210325367.5A CN115192626A (zh) | 2022-03-29 | 2022-03-29 | 一种通风活络、散结保健、痛风止痛制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115192626A true CN115192626A (zh) | 2022-10-18 |
Family
ID=83574853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210325367.5A Pending CN115192626A (zh) | 2022-03-29 | 2022-03-29 | 一种通风活络、散结保健、痛风止痛制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115192626A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103212011A (zh) * | 2013-04-28 | 2013-07-24 | 赵凡涛 | 一种健骨止痛药膏及其制备方法 |
CN103735765A (zh) * | 2014-01-09 | 2014-04-23 | 贵州康琦药械有限公司 | 一种活络止痛贴及其制备方法 |
CN105688148A (zh) * | 2016-03-04 | 2016-06-22 | 孙月新 | 一种祛风通络的中药组合物及制备方法及使用该中药组合物的砂棒 |
-
2022
- 2022-03-29 CN CN202210325367.5A patent/CN115192626A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103212011A (zh) * | 2013-04-28 | 2013-07-24 | 赵凡涛 | 一种健骨止痛药膏及其制备方法 |
CN103735765A (zh) * | 2014-01-09 | 2014-04-23 | 贵州康琦药械有限公司 | 一种活络止痛贴及其制备方法 |
CN105688148A (zh) * | 2016-03-04 | 2016-06-22 | 孙月新 | 一种祛风通络的中药组合物及制备方法及使用该中药组合物的砂棒 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102198262B (zh) | 一种治疗小儿轮状病毒性肠炎的中药制剂及其制备方法 | |
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN105412858A (zh) | 一种糖浆及其制备方法 | |
CN1977899B (zh) | 一种治疗类风湿性关节炎的药物 | |
CN103920027A (zh) | 用于治疗急性黄疸型乙型肝炎的药物及其制备方法 | |
CN102293985B (zh) | 用于治疗冠心病的中药组合物及其制备方法 | |
CN115192626A (zh) | 一种通风活络、散结保健、痛风止痛制剂及其制备方法 | |
CN103623361B (zh) | 用于治疗脑血栓的中药组合物 | |
CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
CN102552841B (zh) | 一种治疗中风后遗症的中药 | |
CN102631496B (zh) | 提高免疫力、抗疲劳的中药组合物 | |
CN110464803A (zh) | 一种用于降低血压的中药组合物及其制备方法 | |
CN103169838A (zh) | 一种治疗乙型肝炎的药物 | |
CN102631486B (zh) | 一种保健组合物 | |
CN117503884B (zh) | 一种治疗抑郁的中药组合物及其制备方法 | |
CN102631506B (zh) | 提高免疫力、抗疲劳的中药组合物 | |
CN106177461A (zh) | 一种治疗神经衰弱综合征的中西药复方制剂及制备方法 | |
CN106309561A (zh) | 一种治疗牙痛的药物及其制备方法 | |
CN105920436A (zh) | 一种用于治疗肺癌的药物制剂及其制备方法 | |
CN105796962A (zh) | 一种安神的药物组合物及其制备方法 | |
CN102631393B (zh) | 一种保健组合物 | |
CN102631493B (zh) | 一种保健组合物 | |
CN104225340A (zh) | 一种治疗白血病的药物及制备方法 | |
CN103251921A (zh) | 一种治疗阴阳两虚的药物组合物及其制备方法及制剂与应用 | |
CN104225560A (zh) | 一种治疗胸阳痹阻型冠心病的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221018 |